Genetic analyses of norovirus GII.4 variants in Finnish children from 1998 to 2013.
Noroviruses (NoVs) are the major causative agents of acute gastroenteritis (AGE) in outbreaks and in sporadic AGE in young children. Since the mid-1990s, NoV genotype GII.4 has been predominant worldwide. New GII.4 variants appear every two to three years, and antigenic variation is focused on the highly variable protruding domain (P2) of the NoV capsid protein which contains the receptor-binding regions. We studied NoV GII.4 variants in cases of endemic AGE in Finnish children from 1998 to 2013. Fecal specimens were collected from cases of AGE followed prospectively in rotavirus vaccine trials from 1998 to 2007, and from children seen at Tampere University Hospital because of AGE from 2006 to 2013. Partial capsid sequences were identified with RT-PCR and sequenced allowing P2 domain alignment and phylogenetic comparison of different GII.4 strains, with virus-like particles (VLPs) developed as candidate vaccines. Of 1495 NoV positive specimens 829 (55%) were of the GII.4 genotype, and altogether twelve GII.4 variants were identified. Identical GII.4 variants were detected in outbreaks of NoVs worldwide. A phylogenetic tree of the amino acid changes in the P2 region showed nine variants that arose over time. Our data indicates that GII.4 continues to be the predominant NoV genotype circulating in the Finnish community, and the changes in the P2 domain over time result in the development of new variants that cause AGE in children. Future NoV vaccines should either induce type specific immunity for each variant or, alternatively, induce broadly reactive protective immunity covering multiple variants.
Vaccine Research Center, School of Medicine, University of Tampere, Biokatu 10, FI-33520 Tampere, Finland. Electronic address: leena.huhti@uta.fi.
Leena
L
Huhti
Vaccine Research Center, School of Medicine, University of Tampere, Biokatu 10, FI-33520 Tampere, Finland.
Vesna
V
Blazevic
Department of Virology, School of Medicine, University of Tampere, Biokatu 10, FI-33520 Tampere, Finland.
Leena
L
Puustinen
Vaccine Research Center, School of Medicine, University of Tampere, Biokatu 10, FI-33520 Tampere, Finland.
Maria
M
Hemming
Vaccine Research Center, School of Medicine, University of Tampere, Biokatu 10, FI-33520 Tampere, Finland.
Marjo
M
Salminen
Vaccine Research Center, School of Medicine, University of Tampere, Biokatu 10, FI-33520 Tampere, Finland.
Timo
T
Vesikari
D000293:Adolescent; D000940:Antigenic Variation; D017250:Caliciviridae Infections / Q000453:epidemiology* / Q000266:history / Q000821:virology*; D002648:Child; D002675:Child, Preschool; D004196:Disease Outbreaks; D000939:Epitopes / Q000276:immunology; D005387:Finland / Q000453:epidemiology; D005759:Gastroenteritis / Q000453:epidemiology* / Q000266:history / Q000821:virology*; D005814:Genes, Viral; D014644:Genetic Variation; D005838:Genotype; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D029322:Norovirus / Q000145:classification / Q000235:genetics* / Q000276:immunology; D010802:Phylogeny; D015995:Prevalence; D017422:Sequence Analysis, DNA
D000939:Epitopes
Acute gastroenteritis; Children; GII.4 genotype; Norovirus; Variants